Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | DRD2 | P14416 | 6/20 | 0.46 |
| ▸ | DRD4 | P21917 | 6/20 | 0.46 |
| ▸ | DRD3 | P35462 | 6/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.43 |
| ▸ | NOTUM | Q6P988 | 4/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.39 |
| ▸ | CXCR1 | P25024 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6768322 | 0.85 | NOTUM (0.60) | RAB9ANPC1MAPTSMN1; SMN2NOTUM | |
| SCHEMBL14829400 | 0.84 | RAB9A (0.50) | RAB9ANPC1DRD2DRD4DRD3 | |
| SCHEMBL6769135 | 0.84 | NOTUM (0.58) | RAB9ANPC1DRD2DRD4DRD3 | |
| SCHEMBL14829453 | 0.80 | NOTUM (0.53) | RAB9ANPC1DRD2DRD4DRD3 | |
| SCHEMBL1456855 | 0.80 | NOTUM (0.53) | RAB9ANPC1DRD2DRD4DRD3 | |
| SCHEMBL6774267 | 0.77 | CNR2 (0.44) | RAB9ANPC1MAPTSMN1; SMN2NOTUM | |
| SCHEMBL6773846 | 0.76 | DRD2 (0.51) | RAB9ANPC1DRD2DRD4DRD3 | |
| SCHEMBL102821 | 0.76 | NPC1 (0.48) | RAB9ANPC1DRD2DRD4DRD3 | |
| SCHEMBL8288449 | 0.76 | NPC1 (0.54) | RAB9ANPC1DRD2DRD4DRD3 | |
| SCHEMBL102268 | 0.76 | RAB9A (0.54) | RAB9ANPC1DRD2DRD4DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6723724-B2 | PSYCHOLOGICAL DISORDERS | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2004-04-20 | — | — | US | disclosed |
| US-20020119983-A1 | Novel isoxazolylalkylpiperazine derivatives having selective biological activity at dopamine D3 or D4 receptor, and preparation thereof | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2002-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020119983-A1 | Novel isoxazolylalkylpiperazine derivatives having selective biological activity at dopamine D3 or D4 receptor, and preparation thereof | DRD4, DRD3, DRD2 | RAB9A 1831/4885NPC1 4523/4885DRD2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.